HRMY Harmony Biosciences Holdings
Company Analysis
Latest News
Harmony Bio Drops 8% on Patent Fear — But Can a Single Drug's Legal Shield Make or Break This Stock?
Shares of Harmony Biosciences tumbled to $33.00 on October 23, extending a steep two-session slide that has erased roughly 15% of the stock's value since...
🔴 Harmony Biosciences is trading 8.41% down in pre-market as Wakix closing arguments leave outcome uncertain
Harmony Biosciences is trading at $33.00, down 8.41%, amid Wakix patent-litigation uncertainty, the clearest recent company-specific overhang. - Closing...
🟢 Harmony Biosciences is trading 4.08% up in pre-market
Harmony Biosciences is trading at $37.50, up 4.08% in pre-market, with no reported catalyst explaining the move. - Available reporting surfaced no new company...
🔴 Harmony Biosciences is trading 6% down today amid AI worries and rising oil prices
Harmony Biosciences is trading at $35.95, down 6.16%, amid a broad selloff; available reporting surfaced no clear company-specific catalyst for the October 22...
Harmony Biosciences Faces WAKIX Patent Risk Despite Strong Cash Generation
An analysis published on October 21, 2026, describes Harmony Biosciences as a strong cash generator, largely because of WAKIX, its narcolepsy treatment. The...
🟢 Harmony Biosciences is trading 7% up in after-hours trading amid advances in major U.S. indexes
Harmony Biosciences is trading at $41.00, up +7.02% in after-hours trading versus the regular-session close, amid broader market gains. - The Nasdaq advanced...
🟢 Harmony Biosciences rises 4.2% — Biotech Sector Surges on M&A Activity and Positive Clinical Trial Data
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🔴 Harmony Biosciences is trading 4.1% down today as CEO retirement news extends pullback
Harmony Biosciences is trading at $36.66, down 4.11%, as the pullback following its CEO succession announcement continues. - CEO Jeffrey Dayno will retire at...
Harmony Biosciences Announces CEO Retirement and Appoints COO as Successor
Harmony Biosciences announced a planned leadership transition where President and CEO Jeffrey M. Dayno, M.D., will retire at the end of the year. The Board has...
🔴 Harmony Biosciences plunges 5% after announcing CEO transition
Harmony Biosciences is trading at $38.11, down 5.38%, following the announcement that Peter Anastasiou will succeed Jeffrey Dayno as President and CEO,...
Harmony Biosciences Shares Fall on Profit-Taking After Pediatric WAKIX Approval
The U.S. Food and Drug Administration approved WAKIX to treat excessive daytime sleepiness in children aged six and older with narcolepsy, expanding the drug’s...
Deutsche Bank Lifts Harmony Biosciences Target as Wakix Patent Fight Tips in the Company's Favor — But Is $42 Already the Ceiling?
Shares of Harmony Biosciences surged 6.1% to $41.98 in pre-market trading October 2, nearly touching the new Deutsche Bank price target of $42, after the bank...
🟢 Harmony Biosciences is trading 6.1% up in pre-market after Deutsche Bank raised its target to $42
Harmony Biosciences is trading 6.09% up at $41.98 in pre-market on October 2, versus the October 1 close of $39.57, after Deutsche Bank raised its price target...
🔴 Harmony Biosciences is trading 4.1% down today amid market-wide risk-off pressure
Harmony Biosciences is trading 4.05% down at $39.59 on September 28, 2026; broader market risk-off pressure is the clearest available context, though no direct...
Harmony Biosciences Bolsters WAKIX Patent Defense, Delaying Generic Entry Until 2030
Oppenheimer reiterated an Outperform rating and $70.00 price target for Harmony Biosciences. The company filed a new patent complaint against a generic...
🔴 Harmony Biosciences is trading 5.4% down in pre-market amid weaker futures and elevated Treasury yields
Harmony Biosciences is trading 5.4% down in pre-market at $38.30, with the decline appearing aligned with broader risk-off conditions, including weaker U.S....
🔴 Harmony Biosciences is trading 4.09% down today amid biotech-sector weakness
Harmony Biosciences is trading at $39.83, down 4.09%, with the decline appearing primarily tied to biotechnology-sector weakness. - No clear company-specific...
🟢 Harmony Biosciences is trading 1.7% up in pre-market amid broad market strength
Harmony Biosciences is trading 1.7% up at $42.75 in pre-market, with the move appearing most consistent with positive broader market sentiment rather than a...
🔴 Harmony Biosciences is trading 0% down in pre-market with no specific catalyst identified
Harmony Biosciences is trading at $42.02 (0%), with no meaningful pre-market change versus the September 18 close. - No fresh September 21 company-specific...
🔴 Harmony Biosciences is trading 6.4% down in pre-market — catalyst remains unclear
Harmony Biosciences is trading 6.4% down at $39.50 after no clear company-specific announcement was identified for September 17, 2026. - Recent company...